Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial

Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial

Item

http://www.wikidata.org/entity/Q34803876

Q34803876

about

Combination Low-Dose Tissue-Type Plasminogen Activator Plus Annexin A2 for Improving Thrombolytic Stroke Therapy Outcomes measured by mortality rates, quality of life and degree of autonomy in the first year in stroke units in Spain.Promising targets of cell death signaling of NR2B receptor subunit in stroke pathogenesis.Low dose tPA plus annexin A2 combination attenuates tPA delayed treatment-associated hemorrhage and improves recovery in rat embolic focal stroke Prestroke Antiplatelet Effect on Symptomatic Intracranial Hemorrhage and Functional Outcome in Intravenous Thrombolysis What causes intracerebral bleeding after thrombolysis for acute ischaemic stroke? Recent insights into mechanisms and potential biomarkers.Does personalized medicine exist and can you test it in a clinical trial?Focal Low and Global High Permeability Predict the Possibility, Risk, and Location of Hemorrhagic Transformation following Intra-Arterial Thrombolysis Therapy in Acute Stroke.THRIVE score predicts clinical and radiological outcome after endovascular therapy or thrombolysis in patients with anterior circulation stroke in everyday clinical practice.Intravenous thrombolysis for acute stroke: current standards and future directions.C5a/C5aR Pathway Plays a Vital Role in Brain Inflammatory Injury via Initiating Fgl-2 in Intracerebral Hemorrhage.Blood-brain barrier breakdown involves four distinct stages of vascular damage in various models of experimental focal cerebral ischemia.Predicting risk of symptomatic intracerebral hemorrhage and mortality after treatment with recombinant tissue-plasminogen activator using SEDAN score.Response to letter regarding article, "Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the Third International Stroke Trial".A Score for Risk of Thrombolysis-Associated Hemorrhage Including Pretreatment with Statins.THRIVE-c score predicts clinical outcomes in Chinese patients after thrombolysis.

P2860

Q26777274-D73E58DE-13A0-4FF5-96D5-E0A3A785927C Q35342198-4359D4B1-7A9F-4D02-AE68-B9655ED68180 Q35576381-6414883D-ED7E-47FE-ACF1-84BE3966AB3D Q36540005-620DC55C-E89E-45EB-8FDD-53061AE11436 Q37343410-33EF74A7-DCBF-4761-9004-268832C63A90 Q38392999-77A4E460-DBA4-424A-AD2C-AB4A5866BDEF Q38568617-B2BD489E-B15F-4572-A16E-EB4C58FCDEC1 Q38680151-A7151D9C-7E51-4962-88E2-1EE085732F8C Q38757416-6C065FDB-BE01-48EC-9CFD-5C3B02044392 Q39028528-75230F89-7F8C-4BFD-AF15-D1620284D937 Q39317676-2804A102-39DD-4752-A2C7-C80428B506D4 Q40515003-D46DEF2B-8FFD-4158-B819-062494698AC7 Q41702122-3A463F3D-6282-4C3F-9BE0-7EE11F9ED1D1 Q42930744-B91A3045-9164-49C6-A87E-0FD544276EF3 Q51765845-E5712F8F-D66B-42BC-BE69-D87E95F76B64 Q52684102-42F28A06-2913-41BE-A74C-244A9769C6A9

P2860

Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial

Item

http://www.wikidata.org/entity/Q34803876

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu